Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study-Reference-Cited by-同舟云学术

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study

Published:2022-09 Issue:9 Volume:22 Page:1303-1312
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Vadrevu Krishna Mohan,Reddy Siddharth,Jogdand Harsh,Ganneru Brunda,Mirza Nizam,Tripathy Virendra Nath,Singh Chandramani,Khalatkar Vasant,Prasanth Siddaiah,Rai Sanjay,Ella Raches,Blackwelder William,Prasad Sai,Ella Krishna

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference26 articles.

1. Addressing the cold reality of mRNA vaccine stability;Crommelin;J Pharm Sci,2021

2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial;Ella;Lancet Infect Dis,2021

3. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial;Ella;Lancet,2021

4. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study;Desai;Lancet Infect Dis,2022

5. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults;Ludvigsson;Acta Paediatr,2020

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption;ACS Medicinal Chemistry Letters;2024-07-22

2. Mucosal vaccines for viral diseases: Status and prospects;Virology;2024-05

3. Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial;BMC Infectious Diseases;2024-04-19

4. Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection;International Journal of Antimicrobial Agents;2024-03

5. Booster vaccination against the SARS-CoV-2: mechanisms and efficiency;Cardiovascular Therapy and Prevention;2024-02-08